Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market – Industry Trends and Forecast to 2030

Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Analysis and Size

Several medical studies show that around 5% to 10% of common cancers are found to be hereditary. Affected people are at a greater risk of getting certain cancers, particularly breast cancer in both men and women, and ovarian cancer in women. The affected people are most likely to get cancer sooner in life, usually before the age of 50 years. There is also an increased risk of attaining other types of cancer, such as melanoma, prostate cancer, and pancreatic cancer, to a lesser extent.

Data Bridge Market Research analyses a growth rate in the hereditary breast and ovarian cancer syndrome treatment market in the forecast period 2023-2030. The expected CAGR of hereditary breast and ovarian cancer syndrome treatment market is tend to be around 5.3% in the mentioned forecast period. The market was valued at USD 6.2 billion in 2022, and it would grow up to USD 9.37 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Scope and Segmentation

Market Definition

Hereditary breast and ovarian cancer syndrome (HBOC) is a type of genetic disorder that increases the risk of ovarian, breast, and other cancers. This syndrome requires wide genetic counselling. Chemoprevention is also a possibility that is used widely for treatment. It can be caused by a mutation that is inherited in families. In this disease, a mutation in only 1 copy of the gene has an increased risk of getting that disease.  

Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Dynamics

Drivers

• Rising Cases of Hereditary breast and ovarian cancer syndrome

The increasing incidence of hereditary breast and ovarian cancer syndrome is projected to enhance the market's growth rate. As per the Indian Council of Medical Research (ICMR), India is expected to have 17.3 lakh new cancer cases by 2020, with more than 8.8 lakh people dying from the disease. Furthermore, breast cancer, which has the highest occurrence of all cancers in women, has grown more common among those under the age of 50 years. Inherited genetic alterations can cause breast or ovarian cancer.

• Increased Demand of Newborn Screening

A consistent increase in demand for newborn screening has led to a rise in sales of DNA testing kits. Growing penetration of newborn screening globally is further helping in revenue growth. Several reforms in genetic testing recommendations have led to the inclusion of multigene panel testing for hereditary cancer into clinical practice. Furthermore, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for ovarian, breast and colorectal cancers provide information on some cancer risk factors and management. The Virginia Department of General Services Division of Integrated Laboratory Facilities screened around 7,867 newborns for more than 31 genetic and metabolic illnesses in November 2019. Thus, all these screening is boosting the growth of the market.  

Opportunities

• Rising Strategic Developments and Acquisitions

There are several strategies that are being developed to boost the demand of the market. One of the strategies is providing hereditary tests at a price lower than what is by competitors. For instance, Color Genomics began selling its product for USD 259, however products offered by Myriad cost about USD 4,000. The growing affordability of the tests is one of the major drivers of this segment. There have been acquisitions between market players that is helping in expanding the growth. For instance, Quest Diagnostics, which is a supplier of diagnostic information services, announced in January 2020, the all-cash equity acquisition of Blueprint Genetics. As its known that Blueprint Genetics focuses in gene variant interpretation using next-generation sequencing (NGS) and proprietary bioinformatics, with this deal, Quest and Blueprint Genetics will improve patient care and pharmaceutical R&D by growing access to important insights into genetic and rare disorders.

Restraints/Challenges

• Late Drug Approvals

The authorized organizations lead to late approvals of the proposed drugs that further lead to the decline of the market growth. The late approvals hamper the treatment processes thus restricting the growth.

This hereditary breast and ovarian cancer syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hereditary breast and ovarian cancer syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hereditary Breast And Ovarian Cancer Syndrome Treatment Market

COVID-19 had a major impact on the market. For instance, after WHO declared COVID-19 a pandemic, governments globally declared lockdowns. The outbreak negatively impacted the inherited genetic analysis sector. This is because of the incapacity of genetic counsellors to observe clients in person, the high failure of doctors to provide guidance and the inability of the laboratory to do the tests. Additionally, genetic counselors were prohibited from working during government shutdowns because regulatory bodies such as the Centers for Medicaid Services (CMS) did not recognize them as healthcare practitioners.

Recent Development

• In 2022, Illumina, Inc. launched the in vitro diagnostic (IVD) kit, a cancer RNA sequencer. The release resulted in the development of the sequencing product line, which is followed by post market approval. It is anticipated to show a linear market growth

Global Hereditary Breast And Ovarian Cancer Syndrome Treatment Market Scope

The hereditary breast and ovarian cancer syndrome treatment market is segmented on the basis of diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Hormonal Therapy
• Chemoprevention
• Tamoxifen
• Others
• Genetic Counseling
• Medication
• Lynparza
• Talazoparib
• Rucaparib
• Niraparib
• Others

Diagnosis

• Genetic Testing
• Magnetic Resonance Imaging (MRI)
• Mammography
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

    Hereditary Breast And Ovarian Cancer Syndrome Treatment Regional Analysis/Insights

The hereditary breast and ovarian cancer syndrome treatment market is analyzed and market size insights and trends are provided by diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period because of the increasing incidence of hereditary breast and ovarian cancer syndrome treatment and increasing geriatric population in this region. Furthermore, increasing presence of several major key players and unhealthy lifestyle of people will further boost the market’s growth rate in this region.

Asia-Pacific is considered to grow over the coming years because of the growing penetration of novel cancer drugs and increasing healthcare expenditure in this region. Furthermore, rising government initiatives will further boost the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Hereditary Breast And Ovarian Cancer Syndrome Treatment Share Analysis

The hereditary breast and ovarian cancer syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hereditary breast and ovarian cancer syndrome treatment market

Key players operating in the hereditary breast and ovarian cancer syndrome treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• LEO Pharma A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India), Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Fresenius Kabi AG (Germany)
• Amneal Pharmaceuticals LLC. (U.S.)

SKU-68489